mRNA vaccine developed for sequential selective organ-to-cell targeting of glioma

Posted on
mrna-vaccine-developed-for-sequential-selective-organ-to-cell-targeting-of-glioma
mRNA vaccine developed for sequential selective organ-to-cell targeting of glioma

References

  1. Huang, X. et al. The landscape of mRNA nanomedicine. Nat. Med. 28, 2273–2287 (2022).

    Google Scholar 

  2. Barbier, A. J., Jiang, A. Y., Zhang, P., Wooster, R. & Anderson, D. G. The clinical progress of mRNA vaccines and immunotherapies. Nat. Biotechnol. 40, 840–854 (2022).

    Google Scholar 

  3. Kumari, M. et al. A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies. J. Biomed. Sci. 29, 68 (2022).

    Google Scholar 

  4. Bahl, K. et al. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol. Ther. 25, 1316–1327 (2017).

    Google Scholar 

  5. Freyn, A. W. et al. A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice. Mol. Ther. 28, 1569–1584 (2020).

    Google Scholar 

  6. Izikson, R. et al. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged >/=65 years: a phase 2, randomised, open-label study. Lancet. Respir. Med. 10, 392–402 (2022).

    Google Scholar 

  7. LaTourette, P. C. et al. Protection against herpes simplex virus type 2 infection in a neonatal murine model using a trivalent nucleoside-modified mRNA in lipid nanoparticle vaccine. Vaccine 38, 7409–7413 (2020).

    Google Scholar 

  8. Wang, K. et al. Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial. Nat. Med. 30, 708–715 (2024).

    Google Scholar 

  9. Rhym, L. H., Manan, R. S., Koller, A., Stephanie, G. & Anderson, D. G. Peptide-encoding mRNA barcodes for the high-throughput in vivo screening of libraries of lipid nanoparticles for mRNA delivery. Nat. Biomed. Eng. 7, 901–910 (2023).

    Google Scholar 

  10. Pattipeiluhu, R. et al. Anionic lipid nanoparticles preferentially deliver mRNA to the hepatic reticuloendothelial system. Adv. Mater. 34, e2201095 (2022).

    Google Scholar 

  11. Miao, L. et al. Synergistic lipid compositions for albumin receptor mediated delivery of mRNA to the liver. Nat. Commun. 11, 2424 (2020).

    Google Scholar 

  12. Parhiz, H., Atochina-Vasserman, E. N. & Weissman, D. mRNA-based therapeutics: looking beyond COVID-19 vaccines. Lancet 403, 1192–1204 (2024).

    Google Scholar 

  13. Tenchov, R., Bird, R., Curtze, A. E. & Zhou, Q. Lipid nanoparticles horizontal line from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. ACS Nano 15, 16982–17015 (2021).

    Google Scholar 

  14. Cheng, Q. et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR–Cas gene editing. Nat. Nanotechnol. 15, 313–320 (2020).

    Google Scholar 

  15. Breda, L. et al. In vivo hematopoietic stem cell modification by mRNA delivery. Science 381, 436–443 (2023).

    Google Scholar 

  16. Lian, X. et al. Bone-marrow-homing lipid nanoparticles for genome editing in diseased and malignant haematopoietic stem cells. Nat. Nanotechnol. 19, 1409–1417 (2024).

    Google Scholar 

  17. Naidu, G. S. et al. A combinatorial library of lipid nanoparticles for cell type-specific mRNA delivery. Adv. Sci. 10, e2301929 (2023).

    Google Scholar 

  18. Qiu, M. et al. Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis. Proc. Natl. Acad. Sci. USA 119, e2116271119 (2022).

    Google Scholar 

  19. Zong, Y., Lin, Y., Wei, T. & Cheng, Q. Lipid nanoparticle (LNP) enables mRNA delivery for cancer therapy. Adv. Mater. 35, e2303261 (2023).

    Google Scholar 

  20. Cullis, P. R. & Felgner, P. L. The 60-year evolution of lipid nanoparticles for nucleic acid delivery. Nat. Rev. Drug. Discov. 23, 709–722 (2024).

    Google Scholar 

  21. Hald Albertsen, C. et al. The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Adv. Drug. Deliv. Rev. 188, 114416 (2022).

    Google Scholar 

  22. Hatit, M. Z. C. et al. Nanoparticle stereochemistry-dependent endocytic processing improves in vivo mRNA delivery. Nat. Chem. 15, 508–515 (2023).

    Google Scholar 

  23. Tilstra, G. et al. Iterative design of ionizable lipids for intramuscular mRNA delivery. J. Am. Chem. Soc. 145, 2294–2304 (2023).

    Google Scholar 

  24. Wu, S. et al. Paracyclophane-based ionizable lipids for efficient mRNA delivery in vivo. J. Control. Release 376, 395–401 (2024).

    Google Scholar 

  25. Cárdenas, M., Campbell, R. A., Yanez Arteta, M., Lawrence, M. J. & Sebastiani, F. Review of structural design guiding the development of lipid nanoparticles for nucleic acid delivery. Curr. Opin. Colloid. Interface. Sci. 66, 101705 (2023).

    Google Scholar 

  26. Xu, Y., Golubovic, A., Xu, S., Pan, A. & Li, B. Rational design and combinatorial chemistry of ionizable lipids for RNA delivery. J. Mater. Chem. B 11, 6527–6539 (2023).

    Google Scholar 

  27. He, Z. et al. A multidimensional approach to modulating ionizable lipids for high-performing and organ-selective mRNA delivery. Angew. Chem. Int. Ed. Engl 62, e202310401 (2023).

    Google Scholar 

  28. Zhang, Y., Sun, C., Wang, C., Jankovic, K. E. & Dong, Y. Lipids and lipid derivatives for RNA delivery. Chem. Rev. 121, 12181–12277 (2021).

    Google Scholar 

  29. Shi, D. et al. To PEGylate or not to PEGylate: immunological properties of nanomedicine’s most popular component, polyethylene glycol and its alternatives. Adv. Drug. Deliv. Rev. 180, 114079 (2022).

    Google Scholar 

  30. Rohner, E., Yang, R., Foo, K. S., Goedel, A. & Chien, K. R. Unlocking the promise of mRNA therapeutics. Nat. Biotechnol. 40, 1586–1600 (2022).

    Google Scholar 

  31. Sanai, N. & Berger, M. S. Surgical oncology for gliomas: the state of the art. Nat. Rev. Clin. Oncol. 15, 112–125 (2018).

    Google Scholar 

  32. Xu, S., Tang, L., Li, X., Fan, F. & Liu, Z. Immunotherapy for glioma: current management and future application. Cancer Lett. 476, 1–12 (2020).

    Google Scholar 

  33. Molinaro, A. M., Taylor, J. W., Wiencke, J. K. & Wrensch, M. R. Genetic and molecular epidemiology of adult diffuse glioma. Nat. Rev. Neurol. 15, 405–417 (2019).

    Google Scholar 

  34. Zhang, Y. & Zhang, Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell. Mol. Immunol. 17, 807–821 (2020).

    Google Scholar 

  35. Riley, R. S., June, C. H., Langer, R. & Mitchell, M. J. Delivery technologies for cancer immunotherapy. Nat. Rev. Drug. Discov. 18, 175–196 (2019).

    Google Scholar 

  36. Hu, Z., Ott, P. A. & Wu, C. J. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat. Rev. Immunol. 18, 168–182 (2018).

    Google Scholar 

  37. Lin, M. J. et al. Cancer vaccines: the next immunotherapy frontier. Nat. Cancer 3, 911–926 (2022).

    Google Scholar 

  38. Liu, J. et al. Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J. Hematol. Oncol. 15, 28 (2022).

    Google Scholar 

  39. Fang, E. et al. Advances in COVID-19 mRNA vaccine development. Signal. Transduct. Target. Ther. 7, 94 (2022).

    Google Scholar 

  40. Lorentzen, C. L., Haanen, J. B., Met, O. & Svane, I. M. Clinical advances and ongoing trials on mRNA vaccines for cancer treatment. Lancet. Oncol. 23, e450–e458 (2022).

    Google Scholar 

  41. Miao, L., Zhang, Y. & Huang, L. mRNA vaccine for cancer immunotherapy. Mol. Cancer 20, 41 (2021).

    Google Scholar 

  42. Mrksich, K., Padilla, M. S. & Mitchell, M. J. Breaking the final barrier: evolution of cationic and ionizable lipid structure in lipid nanoparticles to escape the endosome. Adv. Drug. Deliv. Rev. 214, 115446 (2024).

    Google Scholar 

  43. Hajimolaali, M. et al. Application of chloroquine as an endosomal escape enhancing agent: new frontiers for an old drug. Expert. Opin. Drug. Deliv. 18, 877–889 (2021).

    Google Scholar 

  44. Dang, L., Yen, K. & Attar, E. C. IDH mutations in cancer and progress toward development of targeted therapeutics. Ann. Oncol. 27, 599–608 (2016).

    Google Scholar 

Download references

Related Posts